CN118750581A - 融合蛋白在治疗年龄相关性黄斑变性中的应用 - Google Patents

融合蛋白在治疗年龄相关性黄斑变性中的应用 Download PDF

Info

Publication number
CN118750581A
CN118750581A CN202410790623.7A CN202410790623A CN118750581A CN 118750581 A CN118750581 A CN 118750581A CN 202410790623 A CN202410790623 A CN 202410790623A CN 118750581 A CN118750581 A CN 118750581A
Authority
CN
China
Prior art keywords
eye
weeks
ibi302
once
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410790623.7A
Other languages
English (en)
Chinese (zh)
Inventor
卢淑杰
钱镭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xinda Biotechnology Co ltd
Original Assignee
Innovent Biologics (Suzhou) Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovent Biologics (Suzhou) Co Ltd filed Critical Innovent Biologics (Suzhou) Co Ltd
Publication of CN118750581A publication Critical patent/CN118750581A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN202410790623.7A 2019-12-24 2020-12-23 融合蛋白在治疗年龄相关性黄斑变性中的应用 Pending CN118750581A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN201911346311 2019-12-24
CN2019113463112 2019-12-24
CN2020114410257 2020-12-11
CN202011441025 2020-12-11
PCT/CN2020/138598 WO2021129658A1 (zh) 2019-12-24 2020-12-23 融合蛋白在治疗年龄相关性黄斑变性中的应用
CN202080090126.6A CN114867489A (zh) 2019-12-24 2020-12-23 融合蛋白在治疗年龄相关性黄斑变性中的应用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080090126.6A Division CN114867489A (zh) 2019-12-24 2020-12-23 融合蛋白在治疗年龄相关性黄斑变性中的应用

Publications (1)

Publication Number Publication Date
CN118750581A true CN118750581A (zh) 2024-10-11

Family

ID=76575187

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410790623.7A Pending CN118750581A (zh) 2019-12-24 2020-12-23 融合蛋白在治疗年龄相关性黄斑变性中的应用
CN202080090126.6A Pending CN114867489A (zh) 2019-12-24 2020-12-23 融合蛋白在治疗年龄相关性黄斑变性中的应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080090126.6A Pending CN114867489A (zh) 2019-12-24 2020-12-23 融合蛋白在治疗年龄相关性黄斑变性中的应用

Country Status (8)

Country Link
US (1) US20230056821A1 (enExample)
EP (1) EP4082559A4 (enExample)
JP (2) JP2023509880A (enExample)
CN (2) CN118750581A (enExample)
AU (2) AU2020414152B2 (enExample)
CA (1) CA3165887A1 (enExample)
TW (2) TW202525865A (enExample)
WO (1) WO2021129658A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
FI4185318T3 (fi) 2021-05-17 2025-10-13 Regeneron Pharma Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN117467025B (zh) * 2023-12-28 2024-04-16 上海鼎新基因科技有限公司 一种抗vegf和补体双功能融合蛋白及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014013205A2 (pt) * 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
CN104940926B (zh) * 2014-09-25 2017-09-22 信达生物制药(苏州)有限公司 重组融合蛋白制剂
CN105435222B (zh) * 2014-09-25 2018-05-29 信达生物制药(苏州)有限公司 重组融合蛋白制剂

Also Published As

Publication number Publication date
WO2021129658A1 (zh) 2021-07-01
TWI879855B (zh) 2025-04-11
AU2020414152B2 (en) 2025-02-13
EP4082559A4 (en) 2024-01-03
EP4082559A1 (en) 2022-11-02
CN114867489A (zh) 2022-08-05
AU2025203373A1 (en) 2025-05-29
TW202525865A (zh) 2025-07-01
JP2024167222A (ja) 2024-12-03
TW202128746A (zh) 2021-08-01
AU2020414152A1 (en) 2022-08-04
JP2023509880A (ja) 2023-03-10
CA3165887A1 (en) 2021-07-01
US20230056821A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
US20250268983A1 (en) Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders
TWI879855B (zh) 融合蛋白在治療年齡相關性黃斑變性中的應用
EP3886858B1 (en) Compounds for treatment of eye diseases associated with excessive vascularisation
WO2021048806A1 (en) Methods for treating ocular diseases
KR20220079480A (ko) Sglt-2 억제제를 포함하는 당뇨병성 안질환 예방 또는 치료용 약학적 조성물
US20050043220A1 (en) Methods and compositions for treating macular degeneration
WO2025036488A1 (en) Methods of treating age-related macular degeneration and diabetic macular edema
KR102860024B1 (ko) 이나보글리플로진을 포함하는 안질환의 예방 또는 치료용 약학적 조성물
KR20220051791A (ko) Fas 신호전달 억제용 펩타이드를 포함하는 황반변성 예방 또는 치료용 조성물
KR102879076B1 (ko) Sglt-2 억제제를 포함하는 당뇨병성 안질환 예방 또는 치료용 약학적 조성물
Hakan et al. Evaluation Of The Effectiveness Of Intravitreal Anti-VEGF Injection With Intravitreal Dexamethasone Implant In Patients With Treatment-Resistant Diabetic Macular Edema
HK40125761A (en) Use of a vegf antagonist to treat angiogenic eye disorders
HK40094966A (en) Use of a vegf antagonist to treat diabetic retinopathy
EA046420B1 (ru) Применение антагониста vegf для лечения ангиогенных глазных заболеваний
HK40038974A (en) Use of a vegf antagonist to treat angiogenic eye disorders
HK40038974B (en) Use of a vegf antagonist to treat angiogenic eye disorders
Mahar et al. Visual Outcome Following Intra-vitreal Bevacizumab Injection in Neovascular Age-related Macular Degeneration

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20250307

Address after: Building 2, all-weather research and development center, and basement of Building 6, No. 999 Jinguang Road, Minhang District, Shanghai, 201107

Applicant after: Xinda Biotechnology Co.,Ltd.

Country or region after: China

Address before: No.168 Dongping street, Suzhou Industrial Park, Suzhou, Jiangsu Province

Applicant before: INNOVENT BIOLOGICS (SUZHOU) Co.,Ltd.

Country or region before: China